Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?

Abstract

Treatment for hepatitis C virus is often complicated by anaemia from ribavirin-related haemolysis and bone marrow suppression because of peginterferon alfa. An extensive literature search revealed no reports of drug interactions between ribavirin and oseltamivir. We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza. The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed.

• Authors: M Simón-Talero, M Buti, R Esteban
• Journal: Journal of viral hepatitis (J Viral Hepat) Vol. 19 Suppl 1 Pg. 14-7 (Jan 2012) ISSN: 1365-2893 [Electronic] England
• PMID: 22233409 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2012 Blackwell Publishing Ltd.

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Oseltamivir
• Polyethylene Glycols
• Ribavirin
• peginterferon alfa-2b

Topics

• Adult
• Anemia (chemically induced, physiopathology)
• Antiviral Agents (adverse effects)
• Drug Interactions
• Drug Therapy, Combination
• Female
• Hepacivirus (drug effects)
• Hepatitis C, Chronic (complications, drug therapy, virology)
• Humans
• Influenza A Virus, H1N1 Subtype (drug effects)
• Influenza, Human (complications, drug therapy, virology)
• Interferon alpha-2
• Interferon-alpha (administration & dosage, adverse effects)
• Oseltamivir (adverse effects)
• Polyethylene Glycols (administration & dosage, adverse effects)
• Recombinant Proteins (administration & dosage, adverse effects)
• Ribavirin (administration & dosage, adverse effects)